A new research collaboration is applying fundamental expertise in cellular biology with commercial technology to explore how ...

Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult ... We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies ...

We ended the year with a strong cash position, which we will leverage to achieve meaningful milestones and drive value for all stakeholders as we take the company forward in a new direction,” said ...

The authors have generated important resources such as a reference dataset of early primate development by utilizing single-cell transcriptomic technology together with induced pluripotent stem cells ...

Ubiquitin-specific peptidase 22 (USP22) is identified as a key chromatin-based barrier to human iPSC derivation through a chromatin-focused CRISPR-Cas9 screen. Here, the authors establish an EV ...

After hours: March 24 at 7:32:06 PM EDT ...

After hours: March 21 at 7:00:04 PM EDT Loading Chart for ENLV ...